Ophthalmology
Partner With Us
Advertisement
Conexiant chevron_right Ophthalmology chevron_right Faricimab Shows Greater Hard Exudate Reduction Compared with Aflibercept
Conference News 24th Euretina Congress

Euretina 2024: Faricimab Shows Greater Hard Exudate Reduction Compared with Aflibercept

Faricimab’s dual inhibition mechanism led to a greater reduction in HE compared to aflibercept in DME patients.

Conexiant

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.